Soft drink could enhance effects of an anti-cancer drug
Experiments with an artificial stomach suggest that a popular lemon-lime soft drink could play an unexpected role in improving the effectiveness of an oral anticancer drug. The experiments produced evidence that patients will absorb more of the unnamed drug, tested in Phase I in clinical trials, when taken with "flat" or degassed Sprite. The study appeared in ACS' Molecular Pharmaceutics.
Faraj Atassi and colleagues note that efforts are underway to develop more anticancer medications that patients can take by mouth. However, biological variations among patients — due to variations in stomach acidity and other factors — can reduce the effectiveness of oral anticancer drugs. Such was the case with the unnamed anticancer drug in the study, identified only as "Compound X." There were wide differences in how the drug was absorbed in the first patients who took it.
The scientists combined Compound X with Captisol, a substance that helps improve the solubility of drug ingredients, and turned to the artificial stomach. That glass-and-plastic device is used to study how drugs and foods dissolve through the GI tract. They showed that Sprite seemed to control stomach acidity in a way likely to allow greater absorption of the drug into the body. Based on the results, the scientists suggest that patients in future clinical trials take the drug with Sprite.
Original publication: Christopher S. Polster, Faraj Atassi, Sy-Juen Wu, and David C. Sperry; "Use of Artificial Stomach−Duodenum Model for Investigation of Dosing Fluid Effect on Clinical Trial Variability"; Mol. Pharmaceutics, 2010
Most read news
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Catalent Invests $7.3 Million in Italy - Expands Softgel Encapsulation and Packaging Capabilities in Support of Consumer Health

Bioluminescence - the natural glow - How glowing molecules can also be used in industry
2006 Life Science Industry Awards Finalists
Category:National_Institutes_of_Health_images
Energy sensor as potential target for cancer drugs identified
VaxGen Raises USD 79M Through Sale of Interest in Overseas Biopharmaceutical Manufacturing Facility
